Maternal serum screening for Down syndrome involves biochemical tests such as alpha-fetoprotein ( FP), human chorionic gonadotrophin (hCG) and unconjugated oestriol (uE 3 ), either alone or in combination, that have variable detection and false-positive rates. Choosing a screening protocol requires
Validation of risk estimation using the quadruple test in prenatal screening for Down syndrome
โ Scribed by N. J. Wald; W. J. Huttly
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 65 KB
- Volume
- 19
- Category
- Article
- ISSN
- 0197-3851
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Human chorionic gonadotropin (hCG) free beta-subunit levels were determined in 709 control and 13 Down syndrome urine samples from the second trimester of pregnancy. Results were normalized to urine creatinine concentration and converted to multiples of the unaffected pregnancy medium (MOM). The con
Our purpose was to examine trends over time in the use of prenatal cytogenetic diagnosis by New York State women from 1984 to 1993 in the context of new technologies in prenatal diagnosis and pregnancy management. Data are from the New York State Chromosome Registry and represent 95-98 per cent of a
We aimed to determine how differences in the age at which women had their pregnancies influenced the expected detection and false-positive rates of serum screening for Down 's syndrome (i) between 1970 and 1993 in England and Wales, and (ii) between regions and districts of England and Wales in 1991
This study documents the changes in the percentages of advanced maternal age (AMA) pregnancies in the United States and in Washington State, underlying demographic factors, the impact on the predicted incidence of Down syndrome, and its impact on Down syndrome screening. Data on births in the United